1020325-22-7

Basic information

• Product Name: BenzeneMethanol, 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy]-
• Synonyms: BenzeneMethanol, 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy]-;[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methanol;(3-((5-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)methanol
• CAS NO: 1020325-22-7
• Molecular Formula: C₁₃H₁₀F₃NO₂
• Molecular Weight: 269.2192096
• Mol File: 1020325-22-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BenzeneMethanol, 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzeneMethanol, 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy]-(1020325-22-7)
• EPA Substance Registry System: BenzeneMethanol, 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy]-(1020325-22-7)

Safety Data

• Hazardous Substances Data: 1020325-22-7(Hazardous Substances Data)

Usage

General Description

BenzeneMethanol, 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy]- is a chemical compound that consists of a benzene ring attached to a methanol molecule, with a 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy] side chain. BenzeneMethanol, 3-[[5-(trifluoroMethyl)-2-pyridinyl]oxy]- is used primarily in the pharmaceutical industry as an intermediate in the synthesis of various drugs and other organic compounds. It has also been studied for its potential biological activity and has shown promise as a potential antiviral and antifungal agent. Additionally, it is important to handle this compound with caution, as it is considered hazardous and may have harmful effects on human health and the environment if not properly handled and disposed of.

Upstream product

• 52334-81-3 2-chloro-5-trifluoromethylpyridine 
• 100-83-4 meta-hydroxybenzaldehyde 
• 1020333-02-1 3-((5-(trifluoromethyl)pyridin-2-yl)oxy)benzaldehyde 
• 620-24-6 3-Hydroxybenzyl alcohol 

Downstream Products

• 1020325-30-7 2-[3-(chIoromethyl)phenoxy]-5-(trifluoromethyl)pyridine 
• 1428929-05-8 4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]-cyclohexane carboxylic acid 
• 1428926-09-3 N-(5-chlorothiazol-2-yl)-4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]cyclohexanecarboxamide 
• 1428926-15-1 N-[4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]cyclohexyl]pyridine-3-carboxamide 
• 1428926-16-2 6-methyl-N-[4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]-methylene]cyclohexyl]pyridine-3-carboxamide 
• 1428926-17-3 N-[(3E)-3-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]-cyclohexyl]pyrazine-2-carboxamide 
• 1428929-04-7 ethyl 4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]-cyclohexane carboxylate 
• 1428929-08-1 4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]-cyclohexanamine 
• 1428929-06-9 2-[3-(1,4-dioxaspiro[4.5]decan-8-ylidenemethyl)phenoxy]-5-(trifluoromethyl) pyridine 
• 1428929-07-0 4-[[3-[[5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methylene]cyclohexanone 
• 1428929-21-8 4-[[3-[[6-Methyl-5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]-methylene]cyclohexanamine 
• 1428929-15-0 [3-[[6-chloro-5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methyl 2,2,2-trifluoroacetate 
• 1428929-16-1 [3-[[6-methyl-5-(trifluoromethyl)-2-pyridyl]oxy]phenyl]methanol 
• 1428929-17-2 6-[3-(chloromethyl)phenoxy]-2-methyl-3-(trifluoromethyl)pyridine 

Relevant articles and documents

Discovery and evaluation of novel FAAH inhibitors in neuropathic pain model

Conceptual design and modification of urea moiety in chemotype PF-3845/04457845, the bench marking irreversible inhibitor of fatty acid amide hydrolase (FAAH), led to discovery of a novel nicotinamide-based lead 12a having reversible mechanism of action.

AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF

The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont

4- [3- (ARYLOXY) BENZYLIDENE] -3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS

The present invention relates to compounds of Formula (I), wherein Ar is optionally substituted phenyl or heteroaryl and X, Y and Z are independently N or CH; or a pharmaceutically acceptable salt thereof; processes for the preparation of the compounds; intermediates used in the preparation of the compounds; compositions containing the compounds; and uses of the compounds in treating diseases or conditions associated with fatty acid amide hydrolase (FAAH) activity.